Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 339

1.

The effect of chronic L-dopa administration on supersensitive pre- and postsynaptic dopaminergic receptors in rat brain.

Reches A, Wagner HR, Jiang D, Jackson V, Fahn S.

Life Sci. 1982 Jul 5;31(1):37-44.

PMID:
7109853
2.

Electroconvulsive treatment and haloperidol: effects on pre- and postsynaptic dopamine receptors in rat brain.

Reches A, Wagner HR, Barkai AI, Jackson V, Yablonskaya-Alter E, Fahn S.

Psychopharmacology (Berl). 1984;83(2):155-8.

PMID:
6431465
3.

The effect of chronic bromocriptine and L-dopa on spiperone binding and apomorphine-induced stereotypy.

Globus M, Bannet J, Lerer B, Belmaker RH.

Psychopharmacology (Berl). 1982;78(1):81-4.

PMID:
6815701
4.

Dopamine receptor changes in response to prolonged treatment with L-dopa.

Groppetti A, Flauto C, Parati E, Vescovi A, Rusconi L, Parenti M.

J Neural Transm Suppl. 1986;22:33-45.

PMID:
2946813
5.

Presynaptic dopamine receptors: insensitivity to kainic acid and the development of supersensitivity following chronic haloperidol.

Bannon MJ, Bunney EB, Zigun JR, Skirboll LR, Roth RH.

Naunyn Schmiedebergs Arch Pharmacol. 1980 Jun;312(2):161-5.

PMID:
6772975
6.

Differential effect of repeated treatment with L-dopa on dopamine-D1 or -D2 receptors.

Parenti M, Flauto C, Parati E, Vescovi A, Groppetti A.

Neuropharmacology. 1986 Mar;25(3):331-4.

PMID:
2871516
7.

Mesolimbic and striatal dopamine receptor supersensitivity: prophylactic and reversal effects of L-prolyl-L-leucyl-glycinamide (PLG).

Chiu P, Rajakumar G, Chiu S, Johnson RL, Mishra RK.

Peptides. 1985 Mar-Apr;6(2):179-83.

PMID:
2863809
8.

Chronic haloperidol does not alter agonist affinity for dopamine receptors in vitro.

Meller E, Bohmaker K, Goldstein M, Schweitzer JW, Friedhoff AJ.

Eur J Pharmacol. 1985 Mar 12;109(3):389-94.

PMID:
3157587
9.

The effect of dopamine receptor agonist treatment on haloperidol-induced supersensitivity in mice.

Fayle P, Jackson DM, Jenkins OF, Lafferty PA.

Pharmacol Biochem Behav. 1985 Nov;23(5):715-20.

PMID:
4080755
10.

Chronic lithium administration has no effect on haloperidol-induced supersensitivity of pre- and postsynaptic dopamine receptors in rat brain.

Reches A, Wagner HR, Jackson V, Fahn S.

Brain Res. 1982 Aug 19;246(1):172-7. No abstract available.

PMID:
6289974
11.

Comparison of the effects of haloperidol, remoxipride and raclopride on "pre"- and postsynaptic dopamine receptors in the rat brain.

Magnusson O, Fowler CJ, Mohringe B, Wijkström A, Ogren SO.

Naunyn Schmiedebergs Arch Pharmacol. 1988 Apr;337(4):379-84.

PMID:
2900472
12.

Receptor changes during chronic dopaminergic stimulation.

Jenner P, Boyce S, Marsden CD.

J Neural Transm Suppl. 1988;27:161-75. Review.

PMID:
2900291
14.

In vivo and in vitro evidence of dopaminergic system down regulation induced by chronic L-DOPA.

Ponzio F, Cimino M, Achilli G, Lipartiti M, Perego C, Vantini G, Algeri S.

Life Sci. 1984 May 28;34(22):2107-16.

PMID:
6145075
15.

Chronic treatment with clozapine, unlike haloperidol, does not induce changes in striatal D-2 receptor function in the rat.

Rupniak NM, Hall MD, Mann S, Fleminger S, Kilpatrick G, Jenner P, Marsden CD.

Biochem Pharmacol. 1985 Aug 1;34(15):2755-63.

PMID:
4040370
16.

Lithium does not interact with haloperidol in the dopaminergic pathways of the rat brain.

Reches A, Jackson-Lewis V, Fahn S.

Psychopharmacology (Berl). 1984;82(4):330-4.

PMID:
6427824
17.

Role of opiates in striatal D-1 dopamine receptor supersensitivity induced by chronic L-dopa treatment.

Groppetti A, Ceresoli G, Mandelli V, Parenti M.

J Pharmacol Exp Ther. 1990 Jun;253(3):950-6.

PMID:
2162953
18.
20.
Items per page

Supplemental Content

Support Center